Duffy quoted on her research into hospitals expanding long-term payment plans
Kanter discusses the importance of vetting financial conflicts among CDC’s vaccine advisors
Agency Overreach Leaves Patients Untreated
Medicare’s Coverage with Evidence Development program is stifling patient access to innovative FDA-approved products, from heart valve replacements to PET scans for Alzheimer’s. It’s time for a major overhaul.
Grogan quoted on the competitive threat the U.S. faces from Chinese biotech
Leveraging Corporate Tax Rates, Rather Than R&D Credits or Tariffs, Is Key to Supporting U.S. Biomedical Innovation
As cuts to NIH funding and Trump’s drug pricing executive order risk innovation, a new Schaeffer Center white paper analyzes how tax policies influence medical breakthroughs.
How Does Corporate Tax Policy Influence Innovation?
Corporate income tax reductions lead to more innovation within a country or state without raising overall global innovation rates, while R&D tax credits have more limited effects on innovation.
Hospitals Have Steadily Boosted Stipend Pay to Contracted Providers
A study of California hospitals finds growing use of supplemental payments meant to ensure adequate physician staffing in specialty areas.
A Vision for Rebuilding CMS
Strengthening the agency will require answering critically important questions regarding how CMS should be organized and what human capital skills it will need.
2025 Clinical Trial Recruitment Lab (CTRL) Request for Applications
This notice invites applications for projects that leverage innovative technology-based approaches, including AI and machine learning, to overcome recruitment and retention barriers in Alzheimer’s clinical trials.
Financial Vulnerability Affects Emotional Health Throughout Life
Evidence suggests that the number of years lost to economic adversity is equal to or greater than number of years lost due to major risk factors for chronic disease.
Sood discusses his past work with the new NIH director, Jay Bhattacharya
New Alzheimer’s Blood Tests Have the Potential to Supercharge Clinical Trials
Clinical trials for Alzheimer’s disease typically take longer than those in other therapeutic areas, but new blood tests that aid in diagnosis could speed up progress.
Padula provides insight on how rare disease therapies are influencing new drug pricing trends
Expanded coverage of GLP-1s is “probably the single most effective policy” for improving public health, Goldman says
Ensuring Most-Favored Nation Drug Pricing Doesn’t Sicken Us
Lowering drug prices to European benchmarks would ultimately reduce innovation and make Americans less healthy. Instead, a drug pricing system based on U.S. values would enhance access and support medical progress.
Testimony on IRA Implementation’s Threat to Medicine
The Inflation Reduction Act’s drug pricing provisions threaten continued therapeutic advances. Meanwhile, early implementation of its Part D benefit redesign has likely increased out-of-pocket costs for many Medicare beneficiaries.
The Price of Survival, Paid in Advance
A comparison of hospital policies in the U.S. and India offers insight into how different countries value care.
Many firms producing knockoff weight-loss drugs are “pushing the envelope” on legal requirements for compounders, Schiller says
Improved Health Has Not Boosted Workforce Prospects for People with Diabetes
The “diabetes paradox” indicates that medical progress alone may not be enough to improve economic outcomes in the diabetes population.